• Data demonstrate a 35 percent reduction in risk of death
  • Lifyorli, in combination with nab-paclitaxel, added to NCCN Guidelines® as a preferred regimen
  • Lifyorli approved by the FDA in March 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancer. The SGO presentation slides can be found here.